// App-Quantinova.ai

448 : TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.

Researchers

Presenter

  • Robert J. Jones

Principal Investigators

  • Simon J. Crabb

  • John D. Chester

  • Tony Elliott

  • Robert Anthony Huddart

  • Alison J. Birtle

  • Linda Evans

  • Jason Francis Lester

  • Chao Huang

  • Angela Claire Casbard

  • Tracie-Ann Madden

  • Gareth Griffiths

Medical Centers

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust, Manchester, United Kingdom

  • Weston Park Hospital, Sheffield, United Kingdom

  • Velindre Cancer Centre, Cardiff

  • Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom

  • University of Southampton, Southampten, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Folate Hydrolase 1

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Vandetanib

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Cancer Research UK  and AstraZeneca

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved